LMR Partners’s Agile Therapeutics AGRX Stock Holding History

LMR Partners’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-22	Closed	-$59K	–	1264
2021 Q2	$59K	Buy	+22	New	+$72.5K	﹤0.01%	964
2017 Q3	–	Sell	-28	Closed	-$211K	–	594
2017 Q2	$211K	Buy	+28	New	+$194K	0.01%	517

Other funds holding AGRX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LMR Partners's AGRX Position: Q3 2021 in Review

LMR Partners sold out of Agile Therapeutics (AGRX) in Q3 2021, closing a stake of 22 shares — an estimated $59K sold.

LMR Partners first reported a position in AGRX in Q2 2017 and held it in 2 quarters. The position peaked at $211K in Q2 2017. 49 funds tracked by Wall St. Rank hold AGRX as of Q3 2021.

LMR Partners reported no remaining Agile Therapeutics position as of Q3 2021 after selling out during the quarter.
LMR Partners sold 22 Agile Therapeutics shares in Q3 2021, an estimated $59K.
LMR Partners first reported a position in Agile Therapeutics in Q2 2017 and held it in 2 quarters.
LMR Partners's Agile Therapeutics position peaked at $211K in Q2 2017.
49 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.